{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:51:05Z","timestamp":1786650665388,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Niger Med J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/0300-1652.108884","type":"journal-article","created":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T11:06:49Z","timestamp":1363345609000},"page":"1","source":"Crossref","is-referenced-by-count":15,"title":["<i>Helicobacter pylori<\/i>\n                    eradication therapy: A review of current trends"],"prefix":"10.4103","volume":"54","author":[{"given":"AB","family":"Olokoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OA","family":"Obateru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MO","family":"Bojuwoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0300-1652.108884-1","first-page":"604","volume-title":"Helicobacter Pylori infection","author":"McColl","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0300-1652.108884-2","first-page":"140","volume-title":"Improving Helicobacter pylori eradication regimens","author":"Francois","year":"2006","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/0300-1652.108884-3","first-page":"831","volume-title":"Role of innate immunity in Helicobacter pylori-induced gastric malignancy","author":"Peek","year":"2010","journal-title":"Physiol Rev"},{"key":"key-10.4103\/0300-1652.108884-4","first-page":"240","volume-title":"Risk Factors Associated with Helicobacter pylori Infection among Children in a Defined Geographic Area","author":"Dore","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0300-1652.108884-5","first-page":"1319","volume-title":"Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: A meta-analysis of eradication of Helicobacter pylori","author":"Gisbert","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-6","first-page":"3393","volume-title":"Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: Results of three US multicenter, double-blind trials","author":"Laine","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"key-10.4103\/0300-1652.108884-7","first-page":"1115","volume-title":"Increasing trend of Metronidazole resistance in the treatment of Helicobacter pylori infection.A global challenge","author":"Buta","year":"2010","journal-title":"African J Biotechnol"},{"key":"key-10.4103\/0300-1652.108884-8","first-page":"8","volume-title":"The Maastricht Consensus Report.European Helicobacter Pylori Study Group","author":"Current","year":"1997","journal-title":"Gut"},{"key":"key-10.4103\/0300-1652.108884-9","first-page":"167","volume-title":"Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report","author":"Malfertheiner","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-10","first-page":"719","volume-title":"High eradication rates of Helicobacter pylori with a new sequential treatment","author":"Zullo","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-11","first-page":"335","volume-title":"A historical perspective of Helicobacter gastroduodenitis and its complications","author":"Egan","year":"2007","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"key-10.4103\/0300-1652.108884-12","first-page":"523","volume-title":"Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts","author":"Parente","year":"2003","journal-title":"Dig Liver Dis"},{"key":"key-10.4103\/0300-1652.108884-13","first-page":"2313","volume-title":"Third-line rescue therapy for Helicobacter pylori infection","author":"Cianci","year":"2006","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0300-1652.108884-14","first-page":"385","volume-title":"Helicobacter pylori acquistion of metronidazole resistance by natural transformation in vitro","author":"Hua","year":"1998","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0300-1652.108884-15","first-page":"789","volume-title":"High efficacy of 1-week doxycycline-and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection","author":"Cammarota","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-16","first-page":"31","volume-title":"Treatment of Helicobacter pylori","author":"Egan","year":"2007","journal-title":"Helicobacter"},{"key":"key-10.4103\/0300-1652.108884-17","first-page":"52","volume-title":"Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly","author":"Dore","year":"2006","journal-title":"Helicobacter"},{"key":"key-10.4103\/0300-1652.108884-18","first-page":"1261","volume-title":"One-week triple vs.quadruple therapy for Helicobacter pylori infection - a randomized trial","author":"Calvet","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-19","first-page":"1143","volume-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","author":"Graham","year":"2010","journal-title":"Gut"},{"key":"key-10.4103\/0300-1652.108884-20","first-page":"789","volume-title":"High efficacy of 1-week doxycycline-and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection","author":"Cammarota","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-21","first-page":"90","volume-title":"\u2032Rescue\u2032 therapy with rifabutin after multiple Helicobacter pylori treatment failures","author":"Gisbert","year":"2003","journal-title":"Helicobacter"},{"key":"key-10.4103\/0300-1652.108884-22","first-page":"24","volume-title":"Review article: Treatment of Helicobacter pylori infection and factors influencing eradication","author":"Qasim","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-23","first-page":"68","volume-title":"Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: A meta-analytical approach","author":"Dore","year":"2000","journal-title":"Dig Dis Sci"},{"key":"key-10.4103\/0300-1652.108884-24","first-page":"7","volume-title":"Efficacy of Helicobacter pylori eradication therapies: A single centre observational study","author":"Beales","year":"2001","journal-title":"BMC Gastroenterol"},{"key":"key-10.4103\/0300-1652.108884-25","first-page":"45","volume-title":"A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses","author":"Gatta","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-26","first-page":"363","volume-title":"Helicobacter pylori \"rescue\" therapy after failure of two eradication treatments","author":"Gisbert","year":"2005","journal-title":"Helicobacter"},{"key":"key-10.4103\/0300-1652.108884-27","first-page":"321","volume-title":"New concepts of resistance in the treatment of Helicobacter pylori infections","author":"Graham","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"key-10.4103\/0300-1652.108884-28","first-page":"1497","volume-title":"Rifampin and rifabutin resistance mechanism in Helicobacter pylori","author":"Heep","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0300-1652.108884-29","first-page":"143","volume-title":"Rifabutin-based Helicobacter pylori eradication \u2032rescue therapy\u2032","author":"Canducci","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-30","first-page":"311","volume-title":"Rifabutin-based \u2032rescue therapy\u2032 for Helicobacter pylori infected patients after failure of standard regimens","author":"Perri","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/0300-1652.108884-31","first-page":"983","volume-title":"Rifabutin.A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy","author":"Brogden","year":"1994","journal-title":"Drugs"},{"key":"key-10.4103\/0300-1652.108884-32","first-page":"70","volume-title":"Adverse reactions to furazolidone and other drugs.A comparative review","author":"Altamirano","year":"1989","journal-title":"Scand J Gastroenterol Suppl"},{"key":"key-10.4103\/0300-1652.108884-33","first-page":"306","volume-title":"Furazolidone-and nitrofurantoin-resistant Helicobacter pylori: Prevalence and role of genes involved in metronidazole resistance","author":"Kwon","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0300-1652.108884-34","first-page":"225","volume-title":"Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures","author":"Treiber","year":"2002","journal-title":"Helicobacter"},{"key":"key-10.4103\/0300-1652.108884-35","first-page":"538","volume-title":"Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy","author":"Heep","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key-10.4103\/0300-1652.108884-36","first-page":"163","volume-title":"Lactoferrin structure and functions","author":"Legrand","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"key-10.4103\/0300-1652.108884-37","first-page":"806","volume-title":"Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: A multicentre study","author":"Zullo","year":"2007","journal-title":"Dig Liver Dis"},{"key":"key-10.4103\/0300-1652.108884-38","first-page":"396","volume-title":"Use of lactoferrin for Helicobacter pylori eradication.Preliminary results","author":"Di","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"key-10.4103\/0300-1652.108884-39","first-page":"785","volume-title":"Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: A double-blind, randomized controlled trial","author":"Choi","year":"2011","journal-title":"J Korean Med Sci"}],"container-title":["Nigerian Medical Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:21:36Z","timestamp":1786648896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0300-1652.108884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"alternative-id":["108884"],"URL":"https:\/\/doi.org\/10.4103\/0300-1652.108884","relation":{},"ISSN":["0300-1652"],"issn-type":[{"value":"0300-1652","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}